ClinicalTrials.gg
Active, not recruitingNCT05406362Updated Mar 17, 2026

Assess Safety and Efficacy of VAD044 in HHT Patients

A Phase 1/2 interventional study of VAD044 Part I and VAD044 Part II in Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Vaderis Therapeutics AG. Active, not recruiting at 7 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Vaderis Therapeutics AG · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients.

Part II: The purpose of this open-label extension following the completion of the randomised double blind treatment and follow-up period (Part I of the study) is to assess the long-term safetty, tolerability and efficacy of VAD044 in adult HHT patients.

Read the detailed description

Part I: After being informed about the study and the potential risks, all patients giving written informed consent will undergo a two months screening and observation period to determine eligibility for study entry. At Day 0, patients who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1:1 ratio to 30mg VAD044 (once daily), 40 mg (once daily) or placebo (once daily).

Part II: Patients who have completed the study Part I can participate in the open-label extension study (Part II).The patients can roll over immediately after last visit of the Part I or at any time at their convenience and according to their availability, but within a timeframe no longer than 8 months after the last visit (visit 12) of the part I. All patients in Part II will receive 30 mg of VAD044 once daily for the first 4 weeks afterwards the daily dose can be increased to 40 mg daily for up to 36 months.

02

Conditions studied

  • Hereditary Hemorrhagic Telangiectasia (HHT)

Keywords

  • Osler-Weber-Rendu disease
  • Arteriovenous Malformations
03

In context

Telangiectasia, Hereditary Hemorrhagic

106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.

This study's enrollment of 75 is above the median of 33 across 61 interventional studies indexed under Telangiectasia, Hereditary Hemorrhagic.

Browse Telangiectasia, Hereditary Hemorrhagic studies →

Lead sponsor

Vaderis Therapeutics AG is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For Part I of the study:

Inclusion Criteria:

  • Diagnosis of HHT by the Curaçao criteria
  • Several epistaxis/week
  • Anaemia
  • COVID-19 vaccination or positive COVID-19 antibody test
  • Patient has given written to participate in Part I

Exclusion Criteria:

  • Type 1 diabetes or uncontrolled type II diabetes (insulin or non-insulin dependent)
  • Active COVID-19 infection
  • active uncontrolled infection or known to be serologically positive for , Hep B, Hep C infection
  • Recent procedures on nasal telangiectases (\<6 weeks)
  • Requiring therapeutic anticoagulation
  • Use of drugs with anti-angiogenic properties in the past 8 weeks
  • laboratory abnormalities

Fort Part II of the study:

Inclusion Criteria:

  • Completion of Part I of the study
  • All adverse events or serious adverse events occuring during Part I of the study have resolved
  • Patient has given written informed consent to participate in Part II

Exclusion Criteria:

- Same as in Part I.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    30 mg

    30 mg VAD044

    Drug: VAD044 Part I · Drug: VAD044 Part II

  • Experimental
    40 mg

    40 mg VAD044

    Drug: VAD044 Part I · Drug: VAD044 Part II

  • Placebo comparator
    Placebo

    Placebo

    Drug: VAD044 Part I

Interventions

  • capsules to be taken once daily for 12 weeks

    Also known as: VAD044 L-Tartrate gelatin capsules

  • capsules to be taken once daily for 36 months

    Also known as: VAD044 L-Tartrate gelatin capsules

06

What researchers measure

Primary outcomes

  1. Part I: Safety and Tolerability

    Type and severity of Adverse Events (AEs)

    Time frame: 12 weeks

  2. Part II: Safety and Tolerability

    Type and severity of Adverse Events (AEs)

    Time frame: 36 months

Secondary outcomes

  1. Part I: Change in Epistaxis episodes

    The number of Epistaxis episodes

    Time frame: 12 weeks

  2. Part I: Change in Epistaxis duration

    Epistaxis duration

    Time frame: 12 weeks

  3. Part I: Change in Epistaxis intensity

    Epistaxis flow intensity

    Time frame: 12 weeks

  4. Part I: Change in Epistaxis Severity Score (ESS)

    ESS used to evaluate the current severity of HHT patient nosebleeds (typically in the last three months) and can help health care providers to evaluate how a patient is responding to treatment. This score ranges from 0-10 and is automatically calculated after answering six simple questions. The higher the score the more severe.

    Time frame: 12 weeks

  5. Part I: Change in Haemoglobin

    Haemoglobin

    Time frame: 12 weeks

  6. Part I: Change Ferritin

    Ferritin

    Time frame: 12 weeks

  7. Part I: Change in blood Transferrin saturation level

    Transferrin saturation level

    Time frame: 12 weeks

  8. Part I: Change in Iron supplementation needs

    Iron supplementation needs

    Time frame: 12 weeks

  9. Part I: Change Blood tranfusions requirements

    Blood tranfusions requirements

    Time frame: 12 weeks

  10. Part I: Change in the Nasal Outcome for Epistaxis in Hereditary Hemorrhagic Telangiectasia score

    The Nasal Outcome for Epistaxis in Hereditary Hemorrhagic Telangiectasia (NOSE HHT questionnaire) wil be used to measure physical, social and emotional impacts of epistaxis. It is a 29-items questionnaire using a Likert scale. A higher score indicates a worse outcome

    Time frame: 12 weeks

  11. Part I: Quality of Life Scale SF-12

    The SF-12 Quality of Life Scale is a scale to evaluate quality of life using 12 questions. In the SF-12, physical (SF12-PCS) and mental (SF12-MCS) component summary scores are calculated as sub-dimensions. The total score of the physical and mental component summary of the scale varies between 0-100. An increase in the score indicates well-being, and a decrease indicates a state of disability.

    Time frame: 12 weeks

  12. Part I: Plasma concentration of VAD044

    Plasma concentration of VAD044

    Time frame: 12 weeks

  13. Part I: Maximum concentration (Cmax) of VAD04

    Maximum concentration (Cmax) of VAD044

    Time frame: 12 weeks

  14. Part I: Time of maximum concentration (Tmax) of VAD044

    Time of maximum concentration (Tmax) of VAD044

    Time frame: 12 weeks

  15. Part I: Area under the curve (exposure to drug) during 24 hours (AUC0-24h) of VAD044

    Area under the curve (exposure to drug) during 24 hours (AUC0-24h) of VAD044

    Time frame: 12 weeks

  16. Part I: Trough concentration (Ctrough) of VAD044

    Trough concentration (Ctrough) of VAD044

    Time frame: 12 weeks

  17. Part I: Pharmacodynamics (PD) of VAD044

    PRP assay to measure the levels of pAKT in the blood in a subset of patients

    Time frame: 12 weeks

  18. Part II: Change in The number of Epistaxis episodes

    The number of Epistaxis episodes

    Time frame: 24 months

  19. Part II: Change in Epistaxis duration

    Epistaxis duration

    Time frame: 24 months

  20. Part II: Change in Epistaxis flow intensity

    Epistaxis flow intensity

    Time frame: 24 months

  21. Part II: Change in Epistaxis Severity Score (ESS)

    ESS used to evaluate the current severity of HHT patient nosebleeds (typically in the last three months) and can help health care providers to evaluate how a patient is responding to treatment. This score ranges from 0-10 and is automatically calculated after answering six simple questions. The higher the score the more severe.

    Time frame: 24 months

  22. Part II: Change in Haemoglobin

    Haemoglobin

    Time frame: 24 months

  23. Part II: Change in Ferritin

    Ferritin

    Time frame: 24 months

  24. Part II: Change in Transferrin saturation level

    Transferrin saturation level

    Time frame: 24 months

  25. Part II: Change in Iron supplementation needs

    Iron supplementation needs

    Time frame: 24 months

  26. Part II: Change in blood tranfusions requirements

    blood tranfusions requirements

    Time frame: 24 months

  27. Part II: Quality of Life Scale SF-12

    The SF-12 Quality of Life Scale is a scale to evaluate quality of life using 12 questions. In the SF-12, physical (SF12-PCS) and mental (SF12-MCS) component summary scores are calculated as sub-dimensions. The total score of the physical and mental component summary of the scale varies between 0-100. An increase in the score indicates well-being, and a decrease indicates a state of disability.

    Time frame: 24 months

07

Study locations

7 sites
08

References and documents

Publications

  • Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gomez Del Olmo V, Hodges PG, Torres-Iglesias R, Berte R, Saint-Mezard P, Lazar H, Benedict N, Barker D, Bernasconi C, Picard D, Buscarini E, Mager HJ. Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia. N Engl J Med. 2025 Nov 27;393(21):2131-2141. doi: 10.1056/NEJMoa2504411. PubMed 41297007 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Jan 2027, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
Jun 6, 2022
StartActual
Jul 18, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05406362
Lead sponsor
Vaderis Therapeutics AG
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jul 18, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Damien Picard
study director · Vaderis Therapeutics AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Engasertib

Start the discussion